Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
01:40pm, Tuesday, 04'th Jun 2024
TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven stu
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
02:20pm, Saturday, 01'st Jun 2024
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-re
2 Generic Drug Makers With Growing Runways
07:02am, Friday, 31'st May 2024
Brand-name drug costs continue to climb, but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. Generics are loved by health insurers, Medicare, and
Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade
06:15am, Thursday, 16'th May 2024
Several drug stocks are at risk as the Federal Trade Commission is going after pharmaceutical companies that it alleges are trying to keep generic drugs at bay from their branded products. The Biden a
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
08:15am, Wednesday, 15'th May 2024
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (T
Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript)
02:35pm, Tuesday, 14'th May 2024
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) BofA Securities 2024 Health Care Conference May 14, 2024 11:40 AM ET Company Participants Jason Gerberry - Managing Director, US Specialty Pharma an
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
10:46am, Monday, 13'th May 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
These 7 Stocks Surged Double-Digits and Have Double-Digits to Go
07:08am, Friday, 10'th May 2024
Earnings reports often catalyze big moves in a stock's price; the bigger the move, the more conviction the market shows. Catalysts for these moves include better-than-expected results, gained traction
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
01:15pm, Thursday, 09'th May 2024
TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.
Teva Pharmaceutical Industries (TEVA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
10:36am, Wednesday, 08'th May 2024
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics co
Teva Pharmaceutical's stock climbs as schizophrenia treatment shows promise
09:15am, Wednesday, 08'th May 2024
Teva Pharmaceutical Industries Ltd.'s American depositary receipts TEVA jumped more than 6% premarket Wednesday after the company reported first-quarter sales that topped expectations and released pos
Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First Quarter
08:53am, Wednesday, 08'th May 2024
Teva stock surged to a five-year high Wednesday after the drugmaker kept its full-year guidance despite missing first-quarter profit views.
Teva Pharm Q1 profit falls short of estimates, revenue gains
07:20am, Wednesday, 08'th May 2024
Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to tre
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
07:00am, Wednesday, 08'th May 2024
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2024. Mr. Richard Francis, Teva's President and CEO,
